Adam C Fields1,2, Scott G Weiner3, Luisa J Maldonado4, Paul M Cavallaro5, Nelya Melnitchouk4, Joel Goldberg4, Matthias F Stopfkuchen-Evans6, Olesya Baker3, Liliana G Bordeianou5, Ronald Bleday7. 1. Division of Colorectal Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. acfields@partners.org. 2. Department of Quality and Safety, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. acfields@partners.org. 3. Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 4. Division of Colorectal Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Division of Colorectal Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 6. Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 7. Division of Colorectal Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. rbleday@bwh.harvard.edu.
Abstract
BACKGROUND: Enhanced recovery after surgery (ERAS) programs are now standard of care for colorectal surgery. Efforts have been aimed at decreasing postoperative opioid consumption. The goal of this study is to evaluate the effect of liposomal bupivacaine transversus abdominis plane (TAP) blocks on opioid use and its downstream effect on rates of ileus and hospital length of stay (LOS). METHODS: We performed a retrospective pre- and postintervention time-trend analysis (2016-2018) of ERAS patients undergoing laparoscopic colorectal surgery at two academic medical centers within the same hospital system. The intervention was liposomal bupivacaine TAP blocks versus standard local infiltration with bupivacaine with a primary outcome of total morphine milligram equivalents (MME) administered within 72 h of surgery. Secondary outcomes included hospital LOS and rate of postoperative ileus. RESULTS: There were 556 patients included at the control hospital, and 384 patients were included at the treatment hospital. Patients at both hospitals were similar with regard to age, body mass index, comorbidities, and surgical indication. In an adjusted time-trend analysis, the treatment hospital was associated with a significant decrease in MME administered (- 15.9 mg, p = 0.04) and hospital LOS (- 0.8 days, p < 0.001). There was no significant decrease in the rate of ileus at the treatment hospital (- 6.9%, p = 0.08). CONCLUSIONS: In a time-trend analysis, the addition of liposomal bupivacaine TAP blocks into the ERAS protocol resulted in significantly reduced opioid use and shorter hospital LOS for patients undergoing surgery at the treatment hospital. Liposomal bupivacaine TAP blocks should be considered for inclusion in the standard ERAS protocol.
BACKGROUND: Enhanced recovery after surgery (ERAS) programs are now standard of care for colorectal surgery. Efforts have been aimed at decreasing postoperative opioid consumption. The goal of this study is to evaluate the effect of liposomal bupivacaine transversus abdominis plane (TAP) blocks on opioid use and its downstream effect on rates of ileus and hospital length of stay (LOS). METHODS: We performed a retrospective pre- and postintervention time-trend analysis (2016-2018) of ERAS patients undergoing laparoscopic colorectal surgery at two academic medical centers within the same hospital system. The intervention was liposomal bupivacaine TAP blocks versus standard local infiltration with bupivacaine with a primary outcome of total morphine milligram equivalents (MME) administered within 72 h of surgery. Secondary outcomes included hospital LOS and rate of postoperative ileus. RESULTS: There were 556 patients included at the control hospital, and 384 patients were included at the treatment hospital. Patients at both hospitals were similar with regard to age, body mass index, comorbidities, and surgical indication. In an adjusted time-trend analysis, the treatment hospital was associated with a significant decrease in MME administered (- 15.9 mg, p = 0.04) and hospital LOS (- 0.8 days, p < 0.001). There was no significant decrease in the rate of ileus at the treatment hospital (- 6.9%, p = 0.08). CONCLUSIONS: In a time-trend analysis, the addition of liposomal bupivacaine TAP blocks into the ERAS protocol resulted in significantly reduced opioid use and shorter hospital LOS for patients undergoing surgery at the treatment hospital. Liposomal bupivacaine TAP blocks should be considered for inclusion in the standard ERAS protocol.
Authors: J Wind; S W Polle; P H P Fung Kon Jin; C H C Dejong; M F von Meyenfeldt; D T Ubbink; D J Gouma; W A Bemelman Journal: Br J Surg Date: 2006-07 Impact factor: 6.939
Authors: Joseph C Carmichael; Deborah S Keller; Gabriele Baldini; Liliana Bordeianou; Eric Weiss; Lawrence Lee; Marylise Boutros; James McClane; Scott R Steele; Liane S Feldman Journal: Surg Endosc Date: 2017-08-03 Impact factor: 4.584
Authors: Malaika S Vlug; Jan Wind; Markus W Hollmann; Dirk T Ubbink; Huib A Cense; Alexander F Engel; Michael F Gerhards; Bart A van Wagensveld; Edwin S van der Zaag; Anna A W van Geloven; Mirjam A G Sprangers; Miguel A Cuesta; Willem A Bemelman Journal: Ann Surg Date: 2011-12 Impact factor: 12.969
Authors: Matthew Torgeson; Joel Kileny; Christopher Pfeifer; Lawrence Narkiewicz; Shawn Obi Journal: J Am Coll Surg Date: 2018-05-01 Impact factor: 6.113
Authors: Amy Copperthwaite; Shaheel Mohammad Sahebally; Zeeshan Muhammad Raza; Liam Devane; Niamh McCawley; David Kearney; John Burke; Deborah McNamara Journal: Ir J Med Sci Date: 2022-05-02 Impact factor: 1.568
Authors: Nainisha Chintalapudi; Avinesh Agarwalla; Jeffrey Bortman; Joana Lu; Hrayr G Basmajian; Nirav H Amin; Joseph N Liu Journal: Clin Orthop Surg Date: 2022-04-26
Authors: Richard H Parrish; Heather Monk Bodenstab; Dustin Carneal; Ryan M Cassity; William E Dager; Sara J Hyland; Jenna K Lovely; Alyssa Pollock; Tracy M Sparkes; Siu-Fun Wong Journal: J Clin Med Date: 2022-09-24 Impact factor: 4.964